Methods and compositions containing Fc fusion proteins for enhancing immune responses

US9296803B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9296803-B2
Application numberUS-201113577990-A
CountryUS
Kind codeB2
Filing dateMar 11, 2011
Priority dateMar 11, 2010
Publication dateMar 29, 2016
Grant dateMar 29, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided are compositions and methods for inhibiting cell growth. The cells that are targeted by the compositions and methods of the invention express an antigen, a mimotope of the antigen, or a CXCR4 chemokine receptor. The method entails administering to an individual a polynucleotide encoding an immunoglobulin Fc and an antigen expressed by the cells or a mimotope of the antigen. The method also involves administering to the individual a composition which contains a polynucleotide encoding an immunoglobulin Fc and an antagonist peptide of a CXCR4 chemokine receptor expressed by the cells. Also provided are proteins encoded by the polynucleotides.

First claim

Opening claim text (preview).

I claim: 1. A method for inhibiting growth of tumor cells in an individual comprising administering to the individual a composition comprising a polynucleotide encoding a protein, wherein the protein encoded by the polynucleotide consists of: an immunoglobulin Fc region and only one amino acid sequence of an antagonist peptide of a receptor expressed by the tumor cells, wherein the only one amino acid sequence of the antagonist peptide of the receptor consists of the sequence KGVSLSYR (SEQ ID NO:6); such that growth of the tumor cells that express the receptor is inhibited subsequent to the administration, and wherein the polynucleotide encoding the protein is present in a recombinant oncolytic vaccinia virus. 2. The method of claim 1 , wherein the Fc is a human IgG1 Fc or human IgG3 Fc. 3. The method of claim 1 , wherein the administration is a systemic administration. 4. The method of claim 1 , wherein the immunoglobulin Fc does not comprise an antigen binding portion of an immunoglobulin.

Assignees

Inventors

Classifications

  • cytotoxic response · CPC title

  • C07K14/521Primary

    Chemokines · CPC title

  • Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title

  • Antineoplastic agents · CPC title

  • comprising antibodies · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9296803B2 cover?
Provided are compositions and methods for inhibiting cell growth. The cells that are targeted by the compositions and methods of the invention express an antigen, a mimotope of the antigen, or a CXCR4 chemokine receptor. The method entails administering to an individual a polynucleotide encoding an immunoglobulin Fc and an antigen expressed by the cells or a mimotope of the antigen. The method …
Who is the assignee on this patent?
Kozbor Danuta, Health Research Inc
What technology area does this patent fall under?
Primary CPC classification C07K14/521. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Mar 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).